U.S. Markets closed

Teva Pharmaceutical Gets Reprieve After Analyst Upgrade

Teva Pharmaceutical Gets Reprieve After Analyst Upgrade

Shares jumped during Monday's session after Oppenheimer analysts upgraded the stock to Outperform with a $12 price target.